Arbutus Biopharma Corporation (ABUS)

[RNsidersbuying]

If Genevant sublicenses the intellectual property, licensed by us to Genevant, we are entitled to receive upon the commercialization of a product developed by such sublicensee the lesser of 20% of the revenue received by Genevant for sublicensing and tiered, low single-digit royalties on product sales by the sublicensee.

Does this mean we can eliminate PFE/BNTX from providing any revenue whatsoever to ABUS as ABUS has not recorded any revenue from Genevant to date? And the PFE/BNTX-vaccine has been commercialized for several quarters?